Donepezil/glycopyrrolate

Drug Profile

Donepezil/glycopyrrolate

Alternative Names: RVT 103

Latest Information Update: 06 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Axovant Sciences
  • Class Antidementias; Indans; Nootropics; Pyrrolidinones; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Alzheimer's disease; Lewy body disease

Most Recent Events

  • 13 Jun 2017 Adverse events data from a phase I trial in Alzheimer's disease and Lewy body dementia released by Axovant Sciences
  • 13 Jun 2017 Axovant Sciences completes a proof of concept phase I trial in Alzheimer's disease and Lewy body dementia (Combination therapy) in USA
  • 07 Nov 2016 Phase-I clinical trials in Alzheimer's disease (Combination therapy) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top